Nimodipine

Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDAResubmission for GTx-104 for the Treatment of Patients with aSAH PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the fiscal year ended March 31, 2026. “Since receipt of the U.S. Food and Drug Administration’s (FDA) Complete Response Letter (CRL) in April 2026, we have been working diligently on addressing the cited items, and we look forward to a constructive discussion with the FDA as we continue to prepare our resubmission,” said Prashant Kohli, CEO of Grace Therapeutics. “FDA approval of our New Drug Application (NDA) for GTx-104 for the treatment of aSAH would represent the first meaningful innovation in the standard of care for these patients in more than 40 years. As evidenced by the response among researchers, practitioners and industry leaders to the presentation of our Phase 3 STRIVE-ON trial results at major medical conferences throughout the fiscal year, we believe there is a significant desire in the marketplace for an intravenously administered nimodipine. We are confident in the robust data package supporting our NDA, and that the issues identified by the FDA can be successfully addressed in our resubmission.” Fiscal 2026 and Recent Corporate Highlights On April 23, 2026, the FDA issued a CRL for the Company’s NDA for GTx-104 for the treatment of patients with aSAH. In the CRL, the FDA referenced certain items in the Chemistry, Manufacturing, and Controls (CMC) and Non-Clinical sections of the application, which Grace believes it can address in a resubmission of its NDA. The cited items are related to additional leachable data time points for commercial product, non-clinical product toxicology risk assessments, and current Good Manufacturing Practices (cGMP) deficiencies with our contract manufacturing organization. No clinical deficiencies were identified. A Type A meeting with the FDA has been scheduled to potentially clarify the path forward and determine the appropriate next steps. The Company expects to provide a regulatory update after the receipt of official meeting minutes. Phase 3 STRIVE-ON trial results were presented at multiple major medical conferences over the last twelve months: 2026 American Academy of Neurology, (April 18-22, 2026, Chicago, IL)Society of Critical Care Medicine’s Critical Care Congress (March 22-24, 2026, Chicago, IL)American Association of Neuroscience Nurses (March 21-24, 2026, Dallas, TX)Society of Vascular and Interventional Neurology (November 19-22, 2025, Orlando, FL)2025 Neurocritical Care Society (September 18-21, 2025, Montreal, Quebec) The U.S. Patent and Trademark Office issued a U.S. Patent No. 12,414,943, titled “Nimodipine Parenteral Administration”. The method of use patent, published on September 16, 2025, covers the dosing regimen for IV administration of nimodipine used in the Phase 3 STRIVE-ON safety trial for GTx-104. Grace Therapeutics has established a multi-layered intellectual property estate for GTx-104, including five patents on the composition of the Company’s formulation of nimodipine, which provide patent protection to 2037. The new patent on the IV dosing regimen for GTx-104 strengthens the Company’s intellectual property position and extends protection to 2043. GTx-104 has also been granted Orphan Drug Designation from the FDA, which provides seven years of marketing exclusivity in United States if certain conditions are met upon FDA approval of the NDA. Fiscal Year 2026 Financial Results The Company reported a net loss of $7.8 million, or $0.47 loss per share for the fiscal year ended March 31, 2026, representing a $1.8 million decrease in net loss from $9.6 million, or $0.79 loss per share, for the fiscal year ended March 31, 2025. Total research and development expenses were $2.4 million for the fiscal year ended March 31, 2026, compared with $9.5 million, for the fiscal year ended March 31, 2025. The decrease of $7.1 million was primarily due to the decrease in research activities of $7.5 million driven by the close-out of the GTx-104 pivotal Phase 3 safety clinical trial during the first calendar quarter of 2026, offset by a $0.4 million increase in external consulting and data management costs incurred in support of the NDA of GTx-104, which was submitted to the FDA in June 2025. General and administrative expenses were $8.7 million for the fiscal year ended March 31, 2026, compared to $7.2 million for the fiscal year ended March 31, 2025. The increase of $1.5 million was primarily driven by $0.8 million in non-recurring legal and due diligence costs incurred in connection with strategic initiatives evaluated during the period, as well as increased professional fees and other general and administrative costs of $0.9 million primarily related to pre-commercial planning for GTx-104, offset in part by a decrease in salaries and benefits of $0.2 million primarily a result of decreased headcount. Cash Runway At March 31, 2026, the Company had cash and cash equivalents of $17.0 million, a net decrease of $5.1 million compared to cash and cash equivalents of $22.1 million at March 31, 2025. The Company plans to use its current cash towards resolving the items cited in the FDA’s Complete Response Letter, working capital and other general corporate purposes. The Company believes its existing cash and cash equivalents will be sufficient to sustain planned operations through at least 12 months from the date of this press release. About the STRIVE-ON Trial The STRIVE-ON trial (NCT05995405) was a prospective, randomized open-label trial of GTx-104 compared with nimodipine oral capsules (oral nimodipine) in patients hospitalized with aSAH. 50 patients were administered GTx-104 and 52 patients received oral nimodipine. The primary endpoint was the number of patients with at least one episode of clinically significant hypotension reasonably considered to be caused by the drug, and additional secondary endpoints included safety, clinical, and pharmacoeconomic outcomes. The trial met its primary endpoint, with patients receiving GTx-104 observed to have a 19% reduction in at least one incidence of clinically significant hypotension compared to oral nimodipine (28% versus 35%). Other measures also favored GTx-104 or were comparable between the GTx-104 arm and the oral nimodipine arm, including: 54% patients on GTx-104 had relative dose intensity (RDI) of 95% or higher compared to only 8% on oral nimodipine, and 29% more patients on GTx-104 than on oral nimodipine had favorable functional outcomes at 90 days. In addition, there were fewer intensive care unit (ICU) readmissions, ICU days, and ventilator days for patients receiving GTx-104 versus oral nimodipine. Adverse events were comparable between the two arms and no new safety issues were identified with patients receiving GTx-104. All deaths in both arms of the trial were due to severity of the patient’s underlying disease. There were eight deaths in the GTx-104 arm compared to four deaths in the oral nimodipine arm. The survival status of one patient in the oral nimodipine arm was unknown. No deaths were determined to be related to GTx-104 or oral nimodipine. About aneurysmal Subarachnoid Hemorrhage (aSAH) aSAH is bleeding over the surface of the brain in the subarachnoid space between the brain and the skull, which contains blood vessels that supply the brain. A primary cause of such bleeding is the rupture of an aneurysm in the brain. The result is aSAH, a relatively uncommon type of stroke that accounts for about 5% of all strokes and an estimated 42,500 U.S. hospital treated patients. About GTx-104 GTx-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for IV infusion in aSAH patients to address significant unmet medical needs. The unique nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. GTx-104 provides a convenient IV delivery of nimodipine in the Intensive Care Unit potentially eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Intravenous delivery of GTx-104 also has the potential to lower food effects, drug-to-drug interactions, and eliminate potential dosing errors. Further, GTx-104 has the potential to better manage hypotension in aSAH patients. GTx-104 has been administered in over 200 patients and healthy volunteers and was well tolerated with significantly lower inter- and intra-subject pharmacokinetic variability compared to nimodipine oral capsules. About Grace Therapeutics Grace Therapeutics, Inc. (Grace Therapeutics or the Company) is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Grace Therapeutics’ novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery. Grace Therapeutics’ lead clinical asset, GTx-104, is an IV infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. GTx-104 has been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States if certain conditions are met at NDA approval, and additional intellectual property protection with 52 granted and pending patents. For more information, please visit: www.gracetx.com. Forward-Looking Statements Statements in this press release that are not statements of historical or current fact constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and “forward-looking information” within the meaning of Canadian securities laws (collectively, “forward-looking statements”). Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Grace Therapeutics to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements containing the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “estimates,” “potential,” “should,” “may,” “will,” “plans,” “continue,” “targeted” or other similar expressions to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The forward-looking statements in this press release, including statements regarding the Company’s cash runway and cash position; the future prospects of the Company’s GTx-104 drug candidate; the Company’s belief that there is a significant desire in the marketplace for an alternative to orally administered nimodipine; the Company’s belief that the issues identified by the FDA in the CRL can be successfully addressed in the Company’s resubmission of an NDA for GTx-104; the expected timing and outcome of the Type A meeting with the FDA; the Company’s expectations that the Type A meeting with the FDA will clarify the path forward and determine next steps; the Company’s plans to provide a regulatory update after the receipt of official meeting minutes from such Type A meeting; GTx-104’s potential to bring enhanced treatment options to patients suffering from aSAH; the ability of GTx-104 to potentially eliminate the need for nasogastric tube administration in unconscious or dysphagic patients; the potential of GTx-104 to lower food effects, drug-to-drug interactions, and to eliminate potential dosing errors; the potential of GTx-104 to better manage hypotension in aSAH patients; and the Company’s intellectual property estate for GTx-104, are based upon Grace Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) the outcome of any Type A meeting with the FDA related to GTx-104; (ii) the timing and success of any regulatory resubmission of the NDA for GTx-104; (iii) changes to regulatory pathways; (iv) the Company’s ability to protect its intellectual property for GTx-104; and (v) legislative, regulatory, political and economic developments. The foregoing list of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in the “Special Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2026, to be filed with the Securities and Exchange Commission (“SEC”) and other documents that have been and will be filed by Grace Therapeutics from time to time with the SEC and Canadian securities regulators. All forward-looking statements contained in this press release speak only as of the date on which they were made. Grace Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by applicable securities laws. For more information, please contact: Grace Therapeutics Contact: Prashant Kohli Chief Executive Officer Tel: 609-322-1602 Email: info@gracetx.com www.gracetx.com Investor Relations: LifeSci Advisors Mike Moyer Managing Director Phone: 617-308-4306 Email: mmoyer@lifesciadvisors.com GRACE THERAPEUTICS, INC.Consolidated Balance Sheets March 31, 2026 March 31, 2025 (Expressed in thousands except share data) $ $ Assets Current assets: Cash and cash equivalents 16,977 22,133 Receivables 20 126 Prepaid expenses 383 453 Total current assets 17,380 22,712 Equipment, net 8 15 Intangible assets 41,128 41,128 Goodwill 8,138 8,138 Total assets 66,654 71,993 Liabilities and stockholders’ equity Current liabilities: Trade and other payables 2,146 1,930 Total current liabilities 2,146 1,930 Derivative warrant liabilities — 1,141 Deferred tax liability 612 2,312 Total liabilities 2,758 5,383 Commitments and contingencies Stockholders’ equity: Preferred stock, $0.0001 par value per share; 10,000,000 authorized, none issued and outstanding as of March 31, 2026 and 2025 — — Common stock, $0.0001 par value per share; 100,000,000 authorized; 16,024,026 and 13,718,106 shares issued and outstanding as of March 31, 2026 and 2025, respectively 1 1 Additional paid-in capital 298,413 293,334 Accumulated other comprehensive loss (6,038) (6,038)Accumulated deficit (228,480) (220,687)Total stockholders’ equity 63,896 66,610 Total liabilities and stockholders’ equity 66,654 71,993 GRACE THERAPEUTICS, INC.Consolidated Statements of Loss and Comprehensive Loss Year EndedMarch 31, 2026 Year EndedMarch 31, 2025 (Expressed in thousands, except share and per share data) $ $ Operating expenses Research and development expenses 2,405 9,511 General and administrative expenses 8,672 7,168 Loss from operating activities (11,077) (16,679) Foreign exchange loss (1) (17)Change in fair value of derivative warrant liabilities 900 3,218 Interest and other income, net 685 711 Total other income, net 1,584 3,912 Loss before income tax benefit (9,493) (12,767) Income tax benefit 1,700 3,199 Net loss and total comprehensive loss (7,793) (9,568) Basic and diluted loss per share (0.47) (0.79) Weighted-average number of shares outstanding 16,510,632 12,087,270

Both companies plan to resubmit their products for approval. The FDA has doled out two manufacturing-related complete response letters (CRLs), slamming the brakes on prospective therapies from AbbVie and Grace Therapeutics. For AbbVie, the Chicago drugmaker had been looking to bolster its industry-leading aesthetics portfolio with a fast-acting follow-on to its blockbuster Botox franchise in trenibotulinumtoxinE (TrenibotE). TrenibotE is a first-in-class botulinum neurotoxin serotype E that could comprise a new option for those looking to treat moderate to severe glabellar lines with a short duration of aesthetic effect. AbbVie's experimental injection is meant to last two to three weeks versus the standard months-long duration of effect with Botox.However, the FDA has now requested more information on AbbVie’s manufacturing processes for the product, the company said Thursday. The CRL doesn’t flag any safety or efficacy concerns or request additional clinical data, with AbbVie maintaining confidence that it can address the agency’s comments “promptly” with a “thorough response” in the coming months. "We strongly believe trenibotulinumtoxinE is an important innovation in botulinum toxin science, with the potential to expand options for patients interested in facial aesthetics," AbbVie’s chief scientific officer and EVP of R&D, Roopal Thakkar, M.D., commented in a company release. "Though disappointed, we remain confident in the strength and integrity of our application, and we are well-positioned to respond to the agency's feedback promptly to support completion of the review." The company’s head of aesthetics R&D, Darin Messina, Ph.D., previously said that the product “has the potential to transform the aesthetic toxin treatment landscape for new patients,” as it allows prospective users to experience a quick “trial” use of Botox before going for the longer-lasting version. The injection takes effect as soon as eight hours after administration, whereas standard Botox takes a few days to set in. A new addition to AbbVie’s Botox portfolio could help boost declining sales, with the company's cosmetic Botox revenues slipping 4.3% in 2025. The company made $4.86 billion in global aesthetics sales last year, a 6.1% decline from 2024, of which $2.6 billion came from Botox in its cosmetic uses. The drug franchise is also indicated for several therapeutic uses, including chronic migraines and overactive bladder, from which it collected $3.7 billion in separately reported sales last year. Botox has been a go-to aesthetic treatment since its 2002 approval for its first cosmetic use, with AbbVie taking ownership through its 2020 acquisition of Allergan. The drug is a plasma-derived product that AbbVie has recently been looking to defend against Inflation Reduction Act (IRA) price reductions, citing the IRA’s purported exclusion of plasma drugs from pricing controls. Rejection for Grace Therapeutics AbbVie wasn’t the only drugmaker to receive bad news from the FDA this week. In a separate action, the agency rejected Grace Therapeutics’ injectable form of nimodipine in aneurysmal subarachnoid hemorrhage (aSAH). The asset is coded as GTx-104. The FDA's qualms came down to the non-clinical section of Grace’s drug application, the company said. Specifically, the FDA cited issues with leachables data for product packaging, as well as non-clinical toxicology risk assessments and “product manufacturing deficiencies” at Grace’s contract manufacturing organization. Still, the company is “confident in the robust data package” that supports its submission and believes that the issues can be addressed in a resubmission, CEO Prashant Kohli said. Grace will now request a Type A meeting with the agency to discuss next steps for a potential path forward. Nimodipine has been used to treat patients with subarachnoid hemorrhage since 1988, when it was first introduced as a capsule. In 2013, an oral solution of the drug hit the market to help reduce hospital administration errors that had caused patient deaths in the past.  Grace’s version uses a “unique nanoparticle technology” that supports a water-based formulation of an insoluble drug product for a standard IV infusion, potentially eliminating the need for nasogastric tube administration in patients who are unconscious or otherwise can’t swallow, according to the company. In a study of patients hospitalized with aSAH, those who received Grace’s GTx-104 charted a 19% reduction in at least one incidence of clinically significant hypotension compared to those who were given oral nimodipine. Grace’s therapy was also supported by additional observed benefits, including fewer ICU readmissions and ventilator days, plus a greater percentage of patients who had favorable functional outcomes at 90 days after receiving the drug. There were eight deaths within the GTx-104 arm of the trial, but all deaths across the study were attributed to the severity of the patient’s underlying disease, Grace said. The condition is caused by a ruptured brain aneurysm, which causes bleeding in the subarachnoid space between the brain and the skull and can lead to aSAH, an uncommon type of stroke with a high mortality rate.